{"id":18866,"date":"2026-09-25T08:50:55","date_gmt":"2026-09-25T11:50:55","guid":{"rendered":"https:\/\/www.biolabeco.com.br\/?post_type=imprensa&p=18866"},"modified":"2026-09-30T16:32:29","modified_gmt":"2026-09-30T19:32:29","slug":"%e7%94%9f%e7%89%a9%e5%ae%9e%e9%aa%8c%e5%ae%a4%e5%b7%b2%e8%a2%ab%e5%8c%bb%e8%8d%af%e4%b8%93%e5%88%a9%e6%b1%a0%ef%bc%88mpp%ef%bc%89%e9%80%89%e4%b8%ad%ef%bc%8c%e8%b4%9f%e8%b4%a3%e9%94%80%e5%94%ae","status":"publish","type":"imprensa","link":"https:\/\/www.biolabeco.com.br\/zh\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/","title":{"rendered":"Biolab & Co. \u88ab Medicines Patent Pool (MPP) \u9009\u62e9\uff0c\u8d1f\u8d23\u9500\u552e\u4e00\u79cd\u65b0\u578b\u6297\u6d41\u611f\u75c5\u6bd2\u836f\u7269"},"content":{"rendered":"

Grupo brasileiro est\u00e1 entre as farmac\u00eauticas selecionadas do acordo de licenciamento volunt\u00e1rio firmado entre a MPP e a Roche<\/em><\/p>\n\n\n\n

Biolab & Co. \u88ab Medicines Patent Pool (MPP) \u9009\u4e2d\uff0c\u4e3a\u5df4\u897f\u5e02\u573a\u63d0\u4f9b\u7f57\u6c0f\u516c\u53f8\u7684\u6297\u75c5\u6bd2\u836f\u7269 baloxavir marboxil\uff0c\u8be5\u836f\u7269\u662f\u4e00\u79cd\u65b0\u578b\u6280\u672f\uff0c\u7528\u4e8e\u6cbb\u7597\u6d41\u611f\u3002.<\/p>\n\n\n\n

O an\u00fancio foi feito em 24 de setembro, em evento paralelo \u00e0 Assembleia Geral das Na\u00e7\u00f5es Unidas, em Nova York, dedicado \u00e0 prepara\u00e7\u00e3o global para enfrentar pandemias. A escolha da Biolab & Co., junto a outras farmac\u00eauticas, passou por um criterioso processo de avalia\u00e7\u00e3o t\u00e9cnica e regulat\u00f3ria conduzido pela MPP, com foco em ampliar o acesso ao tratamento nos 129 pa\u00edses abrangidos pelo acordo, para os quais a Biolab & Co. est\u00e1 habilitada a produzir e fornecer o medicamento.<\/p>\n\n\n\n

A MPP \u00e9 uma organiza\u00e7\u00e3o internacional de sa\u00fade p\u00fablica, sem fins lucrativos, apoiada pela ONU, criada em 2010. O modelo ganhou relev\u00e2ncia durante a pandemia de Covid-19, quando possibilitou ampliar rapidamente a produ\u00e7\u00e3o de antivirais. Hoje, o MPP \u00e9 apontado por entidades internacionais como um dos instrumentos mais eficazes para antecipar o acesso a tratamentos antes que uma emerg\u00eancia sanit\u00e1ria se instale.<\/p>\n\n\n\n

“Esta sublicen\u00e7a est\u00e1 alinhada \u00e0 nossa miss\u00e3o de desenvolver e entregar solu\u00e7\u00f5es terap\u00eauticas que geram valor para pacientes e m\u00e9dicos, e que cheguem a quem efetivamente precisa”, afirma Fabio Amorosino, Presidente do Grupo Biolab & Co. “Pandemias n\u00e3o marcam hora para acontecer e n\u00e3o podem esperar por negocia\u00e7\u00f5es prolongadas.  Agora estamos prontos, com uma s\u00f3lida base produtiva, para fazer nossa parte no Brasil e na regi\u00e3o.”<\/p>\n\n\n\n

Baloxavir marboxil \u00e9 um antiviral oral de dose \u00fanica recomendado pela Organiza\u00e7\u00e3o Mundial da Sa\u00fade para o tratamento da influenza, incluindo profilaxia ap\u00f3s exposi\u00e7\u00e3o ao v\u00edrus. O escopo de uso previsto no acordo abrange qualquer indica\u00e7\u00e3o aprovada pelo FDA (EUA) ou pela EMA (Europa).<\/p>\n\n\n\n

A partir da sublicen\u00e7a, a Biolab & Co. dar\u00e1 in\u00edcio, por meio da Biolab Farma, uma das seis empresas do grupo, ao processo de desenvolvimento e registro do produto no Brasil.<\/p>","protected":false},"featured_media":18871,"template":"","categories":[1576],"acf":[],"yoast_head":"\nBiolab & Co. \u00e9 escolhida pelo Medicines Patent Pool (MPP) para comercializar novo antiviral contra influenza - Biolab & Co<\/title>\n<meta name=\"description\" content=\"A Biolab & Co. foi selecionada pela Medicines Patent Pool (MPP) para oferecer ao mercado brasileiro o antiviral baloxavir marboxil, da Roche, nova tecnologia indicada para o tratamento da influenza.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biolabeco.com.br\/zh\/\u5a92\u4f53\/\u751f\u7269\u5b9e\u9a8c\u5ba4\u5df2\u88ab\u533b\u836f\u4e13\u5229\u6c60\uff08mpp\uff09\u9009\u4e2d\uff0c\u8d1f\u8d23\u9500\u552e\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biolab & Co. \u00e9 escolhida pelo Medicines Patent Pool (MPP) para comercializar novo antiviral contra influenza\" \/>\n<meta property=\"og:description\" content=\"A Biolab & Co. foi selecionada pela Medicines Patent Pool (MPP) para oferecer ao mercado brasileiro o antiviral baloxavir marboxil, da Roche, nova tecnologia indicada para o tratamento da influenza.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biolabeco.com.br\/zh\/\u5a92\u4f53\/\u751f\u7269\u5b9e\u9a8c\u5ba4\u5df2\u88ab\u533b\u836f\u4e13\u5229\u6c60\uff08mpp\uff09\u9009\u4e2d\uff0c\u8d1f\u8d23\u9500\u552e\/\" \/>\n<meta property=\"og:site_name\" content=\"Biolab & Co\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-30T19:32:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"669\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/\",\"url\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/\",\"name\":\"Biolab & Co. \u00e9 escolhida pelo Medicines Patent Pool (MPP) para comercializar novo antiviral contra influenza - Biolab & Co\",\"isPartOf\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg\",\"datePublished\":\"2026-09-25T11:50:55+00:00\",\"dateModified\":\"2026-09-30T19:32:29+00:00\",\"description\":\"A Biolab & Co. foi selecionada pela Medicines Patent Pool (MPP) para oferecer ao mercado brasileiro o antiviral baloxavir marboxil, da Roche, nova tecnologia indicada para o tratamento da influenza.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#breadcrumb\"},\"inLanguage\":\"zh-CN\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#primaryimage\",\"url\":\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg\",\"contentUrl\":\"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg\",\"width\":1600,\"height\":669},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biolabeco.com.br\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biolab & Co. \u00e9 escolhida pelo Medicines Patent Pool (MPP) para comercializar novo antiviral contra influenza\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biolabeco.com.br\/#website\",\"url\":\"https:\/\/www.biolabeco.com.br\/\",\"name\":\"Biolab\",\"description\":\"Na Biolab & Co, ci\u00eancia e cuidado caminham juntos. Saiba como promovemos sa\u00fade com responsabilidade socioambiental e tecnologia.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biolabeco.com.br\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-CN\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biolab & Co. \u88ab Medicines Patent Pool (MPP) \u9009\u5b9a\uff0c\u8d1f\u8d23\u9500\u552e\u65b0\u578b\u6297\u6d41\u611f\u836f\u7269 - Biolab & Co.","description":"Biolab & Co. \u88ab Medicines Patent Pool (MPP) \u9009\u4e2d\uff0c\u4e3a\u5df4\u897f\u5e02\u573a\u63d0\u4f9b\u7f57\u6c0f\u516c\u53f8\u7684\u6297\u75c5\u6bd2\u836f\u7269 baloxavir marboxil\uff0c\u8be5\u836f\u7269\u662f\u4e00\u79cd\u65b0\u578b\u6280\u672f\uff0c\u7528\u4e8e\u6cbb\u7597\u6d41\u611f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biolabeco.com.br\/zh\/\u5a92\u4f53\/\u751f\u7269\u5b9e\u9a8c\u5ba4\u5df2\u88ab\u533b\u836f\u4e13\u5229\u6c60\uff08mpp\uff09\u9009\u4e2d\uff0c\u8d1f\u8d23\u9500\u552e\/","og_locale":"zh_CN","og_type":"article","og_title":"Biolab & Co. \u00e9 escolhida pelo Medicines Patent Pool (MPP) para comercializar novo antiviral contra influenza","og_description":"A Biolab & Co. foi selecionada pela Medicines Patent Pool (MPP) para oferecer ao mercado brasileiro o antiviral baloxavir marboxil, da Roche, nova tecnologia indicada para o tratamento da influenza.","og_url":"https:\/\/www.biolabeco.com.br\/zh\/\u5a92\u4f53\/\u751f\u7269\u5b9e\u9a8c\u5ba4\u5df2\u88ab\u533b\u836f\u4e13\u5229\u6c60\uff08mpp\uff09\u9009\u4e2d\uff0c\u8d1f\u8d23\u9500\u552e\/","og_site_name":"Biolab & Co","article_modified_time":"2026-09-30T19:32:29+00:00","og_image":[{"width":1600,"height":669,"url":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/","url":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/","name":"Biolab & Co. \u88ab Medicines Patent Pool (MPP) \u9009\u5b9a\uff0c\u8d1f\u8d23\u9500\u552e\u65b0\u578b\u6297\u6d41\u611f\u836f\u7269 - Biolab & Co.","isPartOf":{"@id":"https:\/\/www.biolabeco.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#primaryimage"},"image":{"@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg","datePublished":"2026-09-25T11:50:55+00:00","dateModified":"2026-09-30T19:32:29+00:00","description":"Biolab & Co. \u88ab Medicines Patent Pool (MPP) \u9009\u4e2d\uff0c\u4e3a\u5df4\u897f\u5e02\u573a\u63d0\u4f9b\u7f57\u6c0f\u516c\u53f8\u7684\u6297\u75c5\u6bd2\u836f\u7269 baloxavir marboxil\uff0c\u8be5\u836f\u7269\u662f\u4e00\u79cd\u65b0\u578b\u6280\u672f\uff0c\u7528\u4e8e\u6cbb\u7597\u6d41\u611f\u3002.","breadcrumb":{"@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#breadcrumb"},"inLanguage":"zh-CN","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/"]}]},{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#primaryimage","url":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg","contentUrl":"https:\/\/www.biolabeco.com.br\/wp-content\/uploads\/2026\/09\/WhatsApp-Image-2026-09-24-at-21.19.27-1.jpeg","width":1600,"height":669},{"@type":"BreadcrumbList","@id":"https:\/\/www.biolabeco.com.br\/imprensa\/biolab-co-e-escolhida-pelo-medicines-patent-pool-mpp-para-comercializar-novo-antiviral-contra-influenza\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biolabeco.com.br\/"},{"@type":"ListItem","position":2,"name":"Biolab & Co. \u00e9 escolhida pelo Medicines Patent Pool (MPP) para comercializar novo antiviral contra influenza"}]},{"@type":"WebSite","@id":"https:\/\/www.biolabeco.com.br\/#website","url":"https:\/\/www.biolabeco.com.br\/","name":"Biolab","description":"\u5728Biolab & Co\uff0c\u79d1\u5b66\u4e0e\u5173\u6000\u76f8\u8f85\u76f8\u6210\u3002\u4e86\u89e3\u6211\u4eec\u5982\u4f55\u901a\u8fc7\u793e\u4f1a\u4e0e\u73af\u5883\u8d23\u4efb\u4ee5\u53ca\u5148\u8fdb\u6280\u672f\u6765\u4fc3\u8fdb\u5065\u5eb7\u3002.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biolabeco.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-CN"}]}},"_links":{"self":[{"href":"https:\/\/www.biolabeco.com.br\/zh\/wp-json\/wp\/v2\/imprensa\/18866"}],"collection":[{"href":"https:\/\/www.biolabeco.com.br\/zh\/wp-json\/wp\/v2\/imprensa"}],"about":[{"href":"https:\/\/www.biolabeco.com.br\/zh\/wp-json\/wp\/v2\/types\/imprensa"}],"version-history":[{"count":1,"href":"https:\/\/www.biolabeco.com.br\/zh\/wp-json\/wp\/v2\/imprensa\/18866\/revisions"}],"predecessor-version":[{"id":18867,"href":"https:\/\/www.biolabeco.com.br\/zh\/wp-json\/wp\/v2\/imprensa\/18866\/revisions\/18867"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biolabeco.com.br\/zh\/wp-json\/wp\/v2\/media\/18871"}],"wp:attachment":[{"href":"https:\/\/www.biolabeco.com.br\/zh\/wp-json\/wp\/v2\/media?parent=18866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biolabeco.com.br\/zh\/wp-json\/wp\/v2\/categories?post=18866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}